NanoLogix, Inc. Multiple International Patent Applications for
BioNanoChanel(TM) and Hydrogen Bioreactor Technology
HUBBARD, Ohio Nov 28, 2007 /PRNewswire-FirstCall via COMTEX/ --
NanoLogix, Inc. (OTC:NNLX - News) a nano-biotechnology company
announces that the company has
submitted international patent applications for
BioNanoChannel(TM) and Hydrogen Bioreactor technology protection
for China, India, Brazil and the EU (European Union).
These filings are necessary prior to the anticipated global
roll-out of the company's BioNanoChanell(TM) rapid
bacteria/microorganism detection technology and also contributes
to the protection of NanoLogix's ongoing Hydrogen Bioreactor
development.
Chris Novak, NanoLogix Director of IP stated: "The
strength and improved focus of the new foreign cases arose from
significant improvements to the originally filed provisional
patent applications. We at NanoLogix are very excited
about the potential for enhancing the patent protection for
these new technologies."
According to Bret Barnhizer, NanoLogix President and CEO, "This
is a step forward for the company in its plans for technological
and business development and sets the stage for one of our
corporate goals of pursuing licensing opportunities for use of
our products internationally. These applications aid us by
ensuring that NanoLogix strengthens their control over the
intellectual property rights to the technology."
About NanoLogix, Inc.
NanoLogix is a leading innovator in the research, development,
and commercialization of nano-biotechnologies, applications
and processes. The Company has 31 granted Patents and 36 Patents
Pending for bioreactor-based Hydrogen Production, revolutionary
rapid medical testing technologies, potential treatments for
sepsis and cancer (via apoptosis), and bioremediation. Information
on NanoLogix is available at
www.nanologixinc.com.
This
press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Those statements include statements regarding the
intent, belief or current expectations of NanoLogix, Inc., and
members of its management as well as the assumptions on which
such
statements are based. Prospective investors are cautioned that
any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation
to update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes
to future operating results.
Contact:
Investor Relations
Bret Barnhizer, CEO
Telephone: 330-534-0800
E-mail:
Bret@nanologixinc.com
